Capsule Endoscopy
On this page
Direct answer
A camera the size of a large vitamin pill, swallowed with a sip of water, transmits two images per second for roughly 8 hours across the small bowel — and after negative bidirectional endoscopy it becomes the first-line investigation of obscure gastrointestinal bleeding, outperforming every other modality in that niche. Its non-bleeding indications are suspected small bowel Crohn's disease (after ileocolonoscopy and cross-sectional imaging), complications of coeliac disease, and suspected small bowel tumours; its governing contraindication is known or suspected obstruction, which is why patients with Crohn's strictures or prior radiation first swallow a patency capsule that dissolves if it cannot pass. Yield is maximised by performing the study close to an active bleeding episode, with a purged bowel and prokinetic-adjusted gastric emptying in selected patients. Findings are graded P1 (uncertain relevance) and P2 (highly relevant — bleeding, angioectasia, ulceration, tumour), and a positive localisation then steers device-assisted enteroscopy — antegrade or retrograde — to the lesion for biopsy or haemostasis.
What you must remember
- The obscure bleeding ladder: persistent or recurrent bleeding (overt or iron-deficiency anaemia) with negative upper endoscopy and colonoscopy defines obscure bleeding; capsule endoscopy precedes deep enteroscopy because it is non-invasive and localises the bleeding site that determines the enteroscope's route.
- Timing is yield: performed within days of overt rebleeding or during ongoing iron deficiency, diagnostic yield rises steeply — a capsule deployed three months after a single melaena finds far less than one deployed in the actively bleeding window.
- Patency capsule logic: a dissolvable capsule of the same dimensions with a radio-opaque tag; safe excretion confirms the lumen will pass the real capsule, permitting the study in stricturing Crohn's disease, prior radiation or adhesive disease.
- Retention definition: capsule retained beyond 2 weeks requiring medical, endoscopic or surgical retrieval; overall risk roughly 1–2 per cent in obscure bleeding but up to around 5 per cent in suspected Crohn's disease — the reason patency testing exists.
- Small bowel Crohn's role: after a normal ileocolonoscopy and cross-sectional enterography, capsule endoscopy identifies small bowel ulceration beyond the reach of the colonoscope and can reclassify disease extent — never before the stricture question is settled.
- Coeliac complications: refractory disease, ulcerative jejunitis and suspected enteropathy-associated lymphoma are assessed by capsule before push or device-assisted enteroscopy with targeted biopsy.
- Preparation evidence: a 2-litre polyethylene glycol preparation with simethicone improves mucosal visibility over fasting alone; routine prokinetics are not standard but are considered in gastroparesis or poor transit.
- Reading discipline: a full read takes 30–60 minutes; roughly 10 per cent of significant lesions are missed within camera blind spots (behind folds, in rapid transit segments), so a negative capsule in iron-deficiency bleeding does not end the workup — repeat capsule, CT enterography or enteroscopy follow.
- Indian access note: with capsule endoscopy concentrated in metropolitan centres and paid largely out-of-pocket, patient selection matters disproportionately; the patency capsule adds cost but converts the Crohn's patient's study from a gamble into a protocol.
A worked obscure-bleeding pathway
A 62-year-old with recurrent melaena and haemoglobin dipping to 6.5 has had a normal upper endoscopy (including a second-look with a colonoscope to the ligament of Treitz) and a normal colonoscopy with good preparation. Obscure overt bleeding, anaemia ongoing — the window is favourable. Iron infusion and capsule within the week: the study shows an actively oozing angioectasia in the proximal jejunum, timed to its transit quartile, which places it within antegrade single-balloon enteroscopy reach. Argon plasma coagulation at enteroscopy closes the episode, with follow-up haemoglobin at three months confirming cure. Had the capsule been negative, the next steps were a repeat capsule during the next bleed, then CT enterography looking for a vascular blush or a small tumour — the sequence matters, and repeating the cheap and invasive tests is not part of it. This is the algorithm that converts "obscure" into "managed", and each branch is a legitimate single-best-answer stem.
How the exam frames it
Three questions dominate. Which investigation after negative bidirectional endoscopy in obscure bleeding — capsule endoscopy, not enteroscopy first, not CT first. Which patients need a patency capsule — known or suspected strictures, Crohn's disease, prior pelvic radiation. And what limits the technology — blind spots with a roughly 10 per cent miss rate, no biopsy, no therapy, retention risk. The Indian viva adds the health-systems angle: how to sequence investigations when the capsule is the family's out-of-pocket expense, and why that makes correct first-time sequencing an ethical as much as a technical skill.
Frequently asked questions
When is capsule endoscopy the first-line investigation?
In obscure gastrointestinal bleeding — persistent or recurrent bleeding or iron-deficiency anaemia after negative upper endoscopy and colonoscopy — where it both detects and localises the lesion.
How is capsule retention prevented in stricturing disease?
By a preliminary patency capsule of identical dimensions that dissolves if held up; safe excretion within about 30 hours permits the diagnostic study.
How does capsule endoscopy fit into suspected Crohn's disease?
After a normal ileocolonoscopy and cross-sectional imaging, it detects small bowel ulceration beyond colonoscopic reach — after stricture exclusion with patency testing.
What factors raise diagnostic yield in obscure bleeding?
Performance close to an active bleeding episode or during ongoing anaemia, adequate bowel preparation, and complete small bowel transit with careful full-length reading.
What are the limitations of capsule endoscopy?
No biopsy or therapy, blind-spot miss rate of roughly 10 per cent, inability to insufflate or inspect behind folds, and retention risk of 1–2 per cent overall (higher in Crohn's disease).